Analysts Anticipate Hologic, Inc. (HOLX) Will Announce Earnings of $0.56 Per Share

Wall Street analysts expect Hologic, Inc. (NASDAQ:HOLX) to announce $0.56 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Hologic’s earnings, with the lowest EPS estimate coming in at $0.55 and the highest estimate coming in at $0.57. Hologic posted earnings per share of $0.50 during the same quarter last year, which indicates a positive year over year growth rate of 12%. The firm is expected to issue its next earnings results on Wednesday, August 1st.

On average, analysts expect that Hologic will report full year earnings of $2.23 per share for the current year, with EPS estimates ranging from $2.22 to $2.26. For the next financial year, analysts anticipate that the company will post earnings of $2.45 per share, with EPS estimates ranging from $2.39 to $2.59. Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Hologic.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, May 2nd. The medical equipment provider reported $0.53 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.53. Hologic had a positive return on equity of 20.86% and a negative net margin of 4.15%. The firm had revenue of $789.30 million for the quarter, compared to analysts’ expectations of $781.23 million. During the same quarter last year, the firm earned $0.50 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year.

A number of research analysts recently weighed in on HOLX shares. Zacks Investment Research cut Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Goldman Sachs Group cut Hologic from a “conviction-buy” rating to a “buy” rating and set a $43.00 target price on the stock. in a report on Monday, March 26th. BidaskClub upgraded Hologic from a “strong sell” rating to a “sell” rating in a report on Wednesday, April 18th. Needham & Company LLC reiterated a “buy” rating and issued a $43.00 target price (down previously from $50.00) on shares of Hologic in a report on Tuesday, May 1st. Finally, Canaccord Genuity cut Hologic from a “buy” rating to a “hold” rating and reduced their target price for the company from $48.00 to $39.00 in a report on Thursday, May 3rd. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and nine have assigned a buy rating to the company. Hologic currently has an average rating of “Hold” and a consensus price target of $44.87.

Hologic stock traded up $1.49 during midday trading on Friday, reaching $40.23. The stock had a trading volume of 4,159,655 shares, compared to its average volume of 2,515,086. Hologic has a twelve month low of $35.10 and a twelve month high of $46.80. The stock has a market capitalization of $10.49 billion, a P/E ratio of 19.67, a PEG ratio of 1.81 and a beta of 0.86. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 1.13.

In other news, VP Karleen Marie Oberton sold 12,196 shares of Hologic stock in a transaction dated Wednesday, May 2nd. The stock was sold at an average price of $40.00, for a total transaction of $487,840.00. Following the sale, the vice president now directly owns 13,825 shares of the company’s stock, valued at $553,000. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Peter J. Valenti III sold 10,107 shares of Hologic stock in a transaction dated Tuesday, May 29th. The stock was sold at an average price of $38.52, for a total value of $389,321.64. The disclosure for this sale can be found here. Insiders sold 29,303 shares of company stock worth $1,148,412 over the last three months. 0.88% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Flinton Capital Management LLC increased its position in shares of Hologic by 9.2% during the fourth quarter. Flinton Capital Management LLC now owns 18,904 shares of the medical equipment provider’s stock worth $808,000 after acquiring an additional 1,598 shares during the last quarter. Jane Street Group LLC increased its position in shares of Hologic by 30.3% during the first quarter. Jane Street Group LLC now owns 6,904 shares of the medical equipment provider’s stock worth $258,000 after acquiring an additional 1,607 shares during the last quarter. United Capital Financial Advisers LLC increased its holdings in Hologic by 34.4% in the first quarter. United Capital Financial Advisers LLC now owns 6,395 shares of the medical equipment provider’s stock valued at $239,000 after buying an additional 1,638 shares during the last quarter. Amalgamated Bank increased its holdings in Hologic by 4.6% in the first quarter. Amalgamated Bank now owns 37,694 shares of the medical equipment provider’s stock valued at $1,408,000 after buying an additional 1,674 shares during the last quarter. Finally, Greenleaf Trust increased its holdings in Hologic by 1.5% in the fourth quarter. Greenleaf Trust now owns 112,101 shares of the medical equipment provider’s stock valued at $4,792,000 after buying an additional 1,675 shares during the last quarter. 93.33% of the stock is currently owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. The company operates through five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Get a free copy of the Zacks research report on Hologic (HOLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit